Ke Liu, M.D., Ph.D.
Chief of Oncology, Office of Cellular, Tissue and Gene Therapies,
Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Dr. Liu is an American Board of Internal Medicine-certified internist and medical oncologist. He received his M.D. from Henan Medical University in China. After working as an investigator at the National Institute of Pharmaceutical and Biologic Products in China, the Chinese FDA equivalent, he moved to the U.S. in 1990 as a visiting scientist in the New York Blood Center. His research focused on the molecular biology of hepatitis C virus, leading to the publication of the first report on the genomes of Chinese HCV strains. Subsequently, he received his Ph.D. in molecular biology from Cornell University’s Graduate School of Medical Sciences.
Dr. Liu completed his internal medical residency training at Albert Einstein College of Medicine in New York. He pursued his medical oncology specialty training at the National Cancer Institute (NCI) at the National Institutes of Health, where he stayed to focus on the clinical research and development of cancer drugs and biologics.
During his tenure at NCI, he served as associate investigator for multiple Phase 1 and 2 clinical trials investigating a variety of new cancer therapeutics. In particular, he served as protocol chairperson and was responsible for developing and conducting a Phase 1/2 clinical trial using genetically modified cells for the treatment of patients with cancer that formed a basis for a patent issued by the U.S. Patent and Trademark Office.
In 2003, Dr. Liu joined the U.S. Federal Drug Administration’s (FDA) Center for Biologics Evaluation and Research as a clinical reviewer and later became a lead medical officer. From 2008 to 2011, he served as a lead medical officer in the FDA’s Center for Drug Evaluation and Research.
Dr. Liu is a practicing medical oncologist and serves as an attending medical oncologist at Washington Veterans Administration Medical Center.